HIV provider endorsement of primary care buprenorphine treatment: A vignette study

Hillary V. Kunins, Nancy L. Sohler, Robert J. Roose, Chinazo O. Cunningham

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Background and Objectives: Opioid dependence is common among HIV-infected persons in the United States. Factors associated with HIV care providers recommending buprenorphine for opioid dependence are poorly defined. Using vignettes, we sought to identify HIV provider characteristics associated with endorsing buprenorphine treatment in primary care. Methods: We used a cross-sectional survey of HIV providers, including 497 physicians, nurse practitioners, and physician assistants attending HIV educational conferences in 2006. Anonymous questionnaires distributed to conference attendees contained one of two vignettes depicting opioid-dependent patients. Respondents recommended type of substance abuse treatment for the vignette patient. Using logistic regression, we tested patient and provider factors associated with HIV provider endorsement of buprenorphine in primary care. Results: Sixteen percent of providers endorsed buprenorphine treatment in primary care for vignette patients. Family physicians and general internists (AOR=2.8, CI=1.1-7.1), African American providers (AOR=3.0, CI=1.3-6.8), and those with previous buprenorphine prescribing experience (AOR=4.6, CI=1.2-17.9) were more likely to endorse buprenorphine treatment in primary care. Conclusions: HIV providers infrequently endorsed buprenorphine treatment in primary care for vignette patients. Generalist and African American providers and those with previous buprenorphine prescribing experience are more likely to endorse buprenorphine treatment in primary care. Targeting generalist and minority providers may be one strategy to promote effective integration of HIV care and opioid addiction treatment.

Original languageEnglish (US)
Pages (from-to)722-728
Number of pages7
JournalFamily Medicine
Volume41
Issue number10
StatePublished - Nov 2009

Fingerprint

Buprenorphine
Primary Health Care
HIV
Opioid Analgesics
Therapeutics
African Americans
Physician Assistants
Nurse Practitioners
Family Physicians
Substance-Related Disorders
Cross-Sectional Studies
Logistic Models
Physicians

ASJC Scopus subject areas

  • Family Practice

Cite this

HIV provider endorsement of primary care buprenorphine treatment : A vignette study. / Kunins, Hillary V.; Sohler, Nancy L.; Roose, Robert J.; Cunningham, Chinazo O.

In: Family Medicine, Vol. 41, No. 10, 11.2009, p. 722-728.

Research output: Contribution to journalArticle

Kunins, Hillary V. ; Sohler, Nancy L. ; Roose, Robert J. ; Cunningham, Chinazo O. / HIV provider endorsement of primary care buprenorphine treatment : A vignette study. In: Family Medicine. 2009 ; Vol. 41, No. 10. pp. 722-728.
@article{d38df418c525412c8d01b1ef603870f4,
title = "HIV provider endorsement of primary care buprenorphine treatment: A vignette study",
abstract = "Background and Objectives: Opioid dependence is common among HIV-infected persons in the United States. Factors associated with HIV care providers recommending buprenorphine for opioid dependence are poorly defined. Using vignettes, we sought to identify HIV provider characteristics associated with endorsing buprenorphine treatment in primary care. Methods: We used a cross-sectional survey of HIV providers, including 497 physicians, nurse practitioners, and physician assistants attending HIV educational conferences in 2006. Anonymous questionnaires distributed to conference attendees contained one of two vignettes depicting opioid-dependent patients. Respondents recommended type of substance abuse treatment for the vignette patient. Using logistic regression, we tested patient and provider factors associated with HIV provider endorsement of buprenorphine in primary care. Results: Sixteen percent of providers endorsed buprenorphine treatment in primary care for vignette patients. Family physicians and general internists (AOR=2.8, CI=1.1-7.1), African American providers (AOR=3.0, CI=1.3-6.8), and those with previous buprenorphine prescribing experience (AOR=4.6, CI=1.2-17.9) were more likely to endorse buprenorphine treatment in primary care. Conclusions: HIV providers infrequently endorsed buprenorphine treatment in primary care for vignette patients. Generalist and African American providers and those with previous buprenorphine prescribing experience are more likely to endorse buprenorphine treatment in primary care. Targeting generalist and minority providers may be one strategy to promote effective integration of HIV care and opioid addiction treatment.",
author = "Kunins, {Hillary V.} and Sohler, {Nancy L.} and Roose, {Robert J.} and Cunningham, {Chinazo O.}",
year = "2009",
month = "11",
language = "English (US)",
volume = "41",
pages = "722--728",
journal = "Family Medicine",
issn = "0742-3225",
publisher = "Society of Teachers of Family Medicine",
number = "10",

}

TY - JOUR

T1 - HIV provider endorsement of primary care buprenorphine treatment

T2 - A vignette study

AU - Kunins, Hillary V.

AU - Sohler, Nancy L.

AU - Roose, Robert J.

AU - Cunningham, Chinazo O.

PY - 2009/11

Y1 - 2009/11

N2 - Background and Objectives: Opioid dependence is common among HIV-infected persons in the United States. Factors associated with HIV care providers recommending buprenorphine for opioid dependence are poorly defined. Using vignettes, we sought to identify HIV provider characteristics associated with endorsing buprenorphine treatment in primary care. Methods: We used a cross-sectional survey of HIV providers, including 497 physicians, nurse practitioners, and physician assistants attending HIV educational conferences in 2006. Anonymous questionnaires distributed to conference attendees contained one of two vignettes depicting opioid-dependent patients. Respondents recommended type of substance abuse treatment for the vignette patient. Using logistic regression, we tested patient and provider factors associated with HIV provider endorsement of buprenorphine in primary care. Results: Sixteen percent of providers endorsed buprenorphine treatment in primary care for vignette patients. Family physicians and general internists (AOR=2.8, CI=1.1-7.1), African American providers (AOR=3.0, CI=1.3-6.8), and those with previous buprenorphine prescribing experience (AOR=4.6, CI=1.2-17.9) were more likely to endorse buprenorphine treatment in primary care. Conclusions: HIV providers infrequently endorsed buprenorphine treatment in primary care for vignette patients. Generalist and African American providers and those with previous buprenorphine prescribing experience are more likely to endorse buprenorphine treatment in primary care. Targeting generalist and minority providers may be one strategy to promote effective integration of HIV care and opioid addiction treatment.

AB - Background and Objectives: Opioid dependence is common among HIV-infected persons in the United States. Factors associated with HIV care providers recommending buprenorphine for opioid dependence are poorly defined. Using vignettes, we sought to identify HIV provider characteristics associated with endorsing buprenorphine treatment in primary care. Methods: We used a cross-sectional survey of HIV providers, including 497 physicians, nurse practitioners, and physician assistants attending HIV educational conferences in 2006. Anonymous questionnaires distributed to conference attendees contained one of two vignettes depicting opioid-dependent patients. Respondents recommended type of substance abuse treatment for the vignette patient. Using logistic regression, we tested patient and provider factors associated with HIV provider endorsement of buprenorphine in primary care. Results: Sixteen percent of providers endorsed buprenorphine treatment in primary care for vignette patients. Family physicians and general internists (AOR=2.8, CI=1.1-7.1), African American providers (AOR=3.0, CI=1.3-6.8), and those with previous buprenorphine prescribing experience (AOR=4.6, CI=1.2-17.9) were more likely to endorse buprenorphine treatment in primary care. Conclusions: HIV providers infrequently endorsed buprenorphine treatment in primary care for vignette patients. Generalist and African American providers and those with previous buprenorphine prescribing experience are more likely to endorse buprenorphine treatment in primary care. Targeting generalist and minority providers may be one strategy to promote effective integration of HIV care and opioid addiction treatment.

UR - http://www.scopus.com/inward/record.url?scp=70450192768&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=70450192768&partnerID=8YFLogxK

M3 - Article

C2 - 19882396

AN - SCOPUS:70450192768

VL - 41

SP - 722

EP - 728

JO - Family Medicine

JF - Family Medicine

SN - 0742-3225

IS - 10

ER -